Adıgüzel Emre, Tecer Duygu, Güzelküçük Ümüt, Taşkaynatan Mehmet Ali, Tan Arif Kenan
Department of Physical Medicine and Rehabilitation, Gülhane Military Medical Academy, TAF Rehabilitation Center, Ankara, Turkey.
Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Medical Faculty of Gazi University, Ankara, Turkey.
Turk J Phys Med Rehabil. 2017 Feb 9;63(2):117-123. doi: 10.5606/tftrd.2017.05882. eCollection 2017 Jun.
This study aims to investigate the efficacy of transforaminal epidural steroid injection (TFESI) on low back pain relief and functional impairments and whether pain provocation during injection has an effect on pain relief in mid-term.
The study, which was conducted between September 2012 and September 2013, included 62 patients with low back pain (38 males, 24 females; median age 45 years; min 22 - max 88 years). All injections were applied under C-arm fluoroscopy guidance, using a mix of betamethasone and lidocaine. A 100 mm Visual Analog Scale (VAS) for pain, Oswestry Disability Index (ODI), and Short Form-36 were administered before the injection, and at post-injection second and 12th weeks. Presence of any pain provocation was questioned during injection.
The most frequent level of intervention was L5 level. Median initial VAS score was 80.0 (50.0;100.0) mm, which was measured as 45.0 (0.0;90.0) mm and 30.0 (0.0;100.0) mm at the post-injection second and 12th weeks, respectively. Median initial ODI score was 25.0 (9.0;43.0) points, which was measured as 17.0 (3.0;38.0) and 12.5 (1.0;38.0) points at the post-injection second and 12th weeks, respectively. All subgroup scores of SF-36 improved significantly during the follow-up period. We detected statistically significant improvements in the outcome measurements at the post-injection second and 12th weeks (p<0.05). There were significant differences between patients with positive and moderate pain provocation in terms of VAS (p=0.004) and ODI (p=0.006) scores.
In this follow-up study, transforaminal epidural steroid injection was found to be effective in both the early period and in the mid-term. Pain provocation was not clinically predictive for better outcome according to the results.
本研究旨在探讨经椎间孔硬膜外类固醇注射(TFESI)缓解腰痛及功能障碍的疗效,以及注射过程中的疼痛激发是否对中期疼痛缓解有影响。
该研究于2012年9月至2013年9月进行,纳入62例腰痛患者(男性38例,女性24例;年龄中位数45岁;最小22岁 - 最大88岁)。所有注射均在C形臂荧光透视引导下进行,使用倍他米松和利多卡因混合液。在注射前、注射后第2周和第12周采用100mm视觉模拟评分法(VAS)评估疼痛、Oswestry功能障碍指数(ODI)以及简短健康调查量表(SF-36)。询问注射过程中是否存在任何疼痛激发情况。
最常干预的节段为L5节段。初始VAS评分中位数为80.0(50.0;100.0)mm,在注射后第2周和第12周分别为45.0(0.0;90.0)mm和30.0(0.0;100.0)mm。初始ODI评分中位数为25.0(9.0;43.0)分,在注射后第2周和第12周分别为17.0(3.0;38.0)分和12.5(1.0;38.0)分。随访期间SF-36的所有亚组评分均显著改善。在注射后第2周和第12周的结局测量中,我们检测到有统计学意义的改善(p<0.05)。在VAS(p = 0.004)和ODI(p = 0.006)评分方面,疼痛激发阳性和中度的患者之间存在显著差异。
在这项随访研究中,发现经椎间孔硬膜外类固醇注射在早期和中期均有效。根据结果,疼痛激发对更好的结局并无临床预测价值。